A preclinical study has looked at immunoPET to detect EGFR expression in bladder cancer, utilising a radioimmunoconjugate 89Zr-DFO-Panitumumab to specifically target and visualise EGFR in orthotopic bladder tumours. Here, EGFR is linked to urinary bladder carcinoma.